Paper Details

  1. Home
  2. Paper Details

Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.

Author: Abdel-AzizAmal Kamal, AbouzidKhaled A M, DoklaEman M E, McPhillieMartin J, MilikSandra N, MinucciSaverio

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

FLT3 and TrKA are kinases that play a role in the development of acute myeloid leukemia (AML). 4ACP, a novel benzimidazole-based small molecule, has shown potent activity against both FLT3 and TrKA, making it a potential dual inhibitor for the treatment of AML. 4ACP exhibited preferential antiproliferative activity against FLT3-ITD positive AML cell lines, suggesting it could be effective in treating AML patients with this specific mutation.
Paper Details　
Original Abstract of the Article :
FMS-like tyrosine kinase 3 (FLT3) enzyme overexpression and mutations are the most common molecular abnormalities associated with acute myeloid leukemia (AML). In addition, recent studies investigated the role of tropomyosin receptor kinase A (TrKA) enzyme fusions in promoting AML growth and surviva...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.bmc.2021.116596

データ提供：米国国立医学図書館（NLM）

A New Weapon in the Fight Against Leukemia: A Dual FLT3/TrKA Inhibitor

Acute myeloid leukemia (AML) is a serious blood cancer. This study investigates the potential of using a dual inhibitor, a compound that targets multiple enzymes, to combat AML. The authors focused on inhibiting both FLT3 and TrKA, two enzymes that play a role in AML development and survival.

A Multi-pronged Approach to Fight AML

The researchers identified a benzimidazole-based compound, 4ACP, that showed potent activity against both FLT3 and TrKA, inhibiting the growth and survival of AML cells. This approach offers a promising strategy for overcoming resistance to existing treatments and improving patient outcomes.

Hope for a Cure

This research offers new hope for AML patients. The development of dual inhibitors, like 4ACP, represents a significant step forward in the fight against this challenging disease. It's essential to support ongoing research efforts that aim to develop innovative treatments for cancer and other life-threatening conditions.

Dr.Camel's Conclusion

Think of this dual inhibitor as a desert warrior, armed with multiple weapons to fight against the relentless sands of AML. This study offers a glimpse into the future of cancer therapy, where targeted and multi-pronged approaches can bring us closer to a cure.

Date :
  1. Date Completed 2022-03-07
  2. Date Revised 2022-03-07
Further Info :

Pubmed ID

35033885

DOI: Digital Object Identifier

10.1016/j.bmc.2021.116596

Related Literature

Article Analysis
・Effects of quizartinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.